Corrigendum to: ASPRE trial: performance of screening for preterm pre-eclampsia: ASPRE trial screening performance (Ultrasound in Obstetrics & Gynecology, (2017), 50, 4, (492-495), 10.1002/uog.18816);ASPRE trial: performance of screening for preterm pre-eclampsia

Ultrasound in Obstetrics and Gynecology

Volumn 50, Issue 4, 2017, Pages 492-495

  Rolnik, D L ^a   Wright, D ^b   Poon, L C Y ^a,c   Syngelaki, A ^a   O'Gorman, N ^a   de Paco Matallana, C ^d   Akolekar, R ^e   Cicero, S ^f   Janga, D ^g   Singh, M ^h   Molina, F S ⁱ   Persico, N ^j   Jani, J C ^k   Plasencia, W ^l   Papaioannou, G ^m   Tenenbaum Gavish, K ⁿ   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e MEDWAY MARITIME HOSPITAL   (United Kingdom)

^f HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^g NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^h SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^k BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^l Grupo Hospiten   (Spain)

^m NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁿ RABIN MEDICAL CENTER   (Israel)

more..

Author keywords

ASPRE trial; first trimester screening; mean arterial pressure; placental growth factor; pre eclampsia; pregnancy associated plasma protein A; pyramid of pregnancy care; uterine artery Doppler

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; PGF PROTEIN, HUMAN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ALGORITHM; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MASS SCREENING; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PREECLAMPSIA; PREGNANCY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; UTERINE ARTERY; YOUNG ADULT;

ADULT; ALGORITHMS; ASPIRIN; BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MASS SCREENING; PLACENTA GROWTH FACTOR; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PROSPECTIVE STUDIES; RESEARCH DESIGN; UTERINE ARTERY; YOUNG ADULT;

EID: 85029859463     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.18950     Document Type: Erratum

References (15)

1. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613–622.
2. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8–15.
3. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, LijmerJG Moher D, Rennie D, de Vet HCW, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF, For the STARD Group. STARD 2015: An updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015; 351: h5527.
4. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in screening for preeclampsia by maternal characteristics and medical history. Am J Obstet Gynecol 2015; 213: 62.e1–10.
5. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 42–48.
6. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30: 742–749.
7. Wright A, Wright D, Ispas A, Poon LC, Nicolaides KH. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 698–706.
8. Tayyar A, Guerra L, Wright A, Wright D, Nicolaides KH. Uterine artery pulsatility index in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 689–697.
9. Wright D, Silva M, Papadopoulos S, Wright A, Nicolaides KH. Serum pregnancy associated plasma protein-A in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 46: 42–50.
10. Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol 2015; 45: 591–598.
11. Robinson HP, Fleming JE. A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 82: 702–710.
12. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: Statement from the international society for the study of hypertension in pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX–XIV.
13. National Collaborating Centre for Women's and Children's Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press, 2010.
14. O' Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M1, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol 2017; 49: 756–760.
15. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122–31.